Publications
Filters: First Letter Of Keyword is D [Clear All Filters]
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Variable selection for optimal treatment decision." Stat Methods Med Res 22, no. 5 (2013): 493-504.
" "Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard." Biometrics 71, no. 2 (2015): 538-47.
"Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
"A trivariate meta-analysis of diagnostic studies accounting for prevalence and non-evaluable subjects: re-evaluation of the meta-analysis of coronary CT angiography studies." BMC Med Res Methodol 14 (2014): 128.
"A trivariate meta-analysis of diagnostic studies accounting for prevalence and non-evaluable subjects: re-evaluation of the meta-analysis of coronary CT angiography studies." BMC Med Res Methodol 14 (2014): 128.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Time-varying latent effect model for longitudinal data with informative observation times." Biometrics 68, no. 4 (2012): 1093-102.
"Time-dependent classification accuracy curve under marker-dependent sampling." Biom J 58, no. 4 (2016): 974-92.
"Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion." J Vet Intern Med 33, no. 2 (2019): 726-734.
"Ten Simple Rules for Effective Statistical Practice." PLoS Comput Biol 12, no. 6 (2016): e1004961.
"Ten Simple Rules for Effective Statistical Practice." PLoS Comput Biol 12, no. 6 (2016): e1004961.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling." Genome Biol 18, no. 1 (2017): 66.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Sufficient dimension reduction via bayesian mixture modeling." Biometrics 67, no. 3 (2011): 886-95.
"Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression." Am J Hum Genet 89, no. 2 (2011): 277-88.
"Statistical methods for multivariate meta-analysis of diagnostic tests: An overview and tutorial." Stat Methods Med Res 25, no. 4 (2016): 1596-619.
"Statistical Methods for Conditional Survival Analysis." J Biopharm Stat 28, no. 5 (2018): 927-938.
"Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials." Contemp Clin Trials 42 (2015): 9-17.
"Statistical inferences for data from studies conducted with an aggregated multivariate outcome-dependent sample design." Stat Med 36, no. 6 (2017): 985-997.
"Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Sparse meta-analysis with high-dimensional data." Biostatistics 17, no. 2 (2016): 205-20.
"SNPpy--database management for SNP data from genome wide association studies." PLoS One 6, no. 10 (2011): e24982.
"A smoothing-based goodness-of-fit test of covariance for functional data." Biometrics 75, no. 2 (2019): 562-571.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"A simple and robust method for multivariate meta-analysis of diagnostic test accuracy." Stat Med 36, no. 1 (2017): 105-121.
"Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI." Neuroimage 56, no. 3 (2011): 890-906.
"Set-valued dynamic treatment regimes for competing outcomes." Biometrics 70, no. 1 (2014): 53-61.
"Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment." J Biopharm Stat 26, no. 2 (2016): 269-79.
"Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion." Lifetime Data Anal 25, no. 3 (2019): 507-528.
"Semiparametric regression for the weighted composite endpoint of recurrent and terminal events." Biostatistics 17, no. 2 (2016): 390-403.
"Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
"Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data." Lifetime Data Anal 26, no. 1 (2020): 85-108.
"Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34.
"Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring." Lifetime Data Anal 17, no. 4 (2011): 566-93.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Semiparametric additive marginal regression models for multiple type recurrent events." Lifetime Data Anal 18, no. 4 (2012): 504-27.
"Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506.
"Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"SCOPE: A Normalization and Copy-Number Estimation Method for Single-Cell DNA Sequencing." Cell Syst 10, no. 5 (2020): 445-452.e6.
"Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23.
"Sample size calculation for studies with grouped survival data." Stat Med 37, no. 27 (2018): 3904-3917.
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707.
"Response to reader reaction." Biometrics 71, no. 1 (2015): 267-273.
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
"Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634.
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
"Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer." Cancer 121, no. 6 (2015): 836-43.
"Prospects and challenges for clinical decision support in the era of big data." JCO Clin Cancer Inform 2 (2018).
"Prospects and challenges for clinical decision support in the era of big data." JCO Clin Cancer Inform 2 (2018).
"Prospects and challenges for clinical decision support in the era of big data." JCO Clin Cancer Inform 2 (2018).
"Probability-enhanced sufficient dimension reduction for binary classification." Biometrics 70, no. 3 (2014): 546-55.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Practical designs for Phase I combination studies in oncology." J Biopharm Stat 26, no. 1 (2016): 150-66.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy." Pharmacogenomics 14, no. 5 (2013): 555-74.
"Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy." Pharmacogenomics 14, no. 5 (2013): 555-74.
"Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis." Influenza Other Respir Viruses 6, no. 2 (2012): 80-6.
"Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354.
"Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation." Biometrics 70, no. 3 (2014): 765-73.
"Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658.
"Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
"Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective." Lifetime Data Anal 23, no. 4 (2017): 585-604.
"Nucleotide excision repair capacity increases during differentiation of human embryonic carcinoma cells into neurons and muscle cells." J Biol Chem 294, no. 15 (2019): 5914-5922.
"Nucleotide excision repair capacity increases during differentiation of human embryonic carcinoma cells into neurons and muscle cells." J Biol Chem 294, no. 15 (2019): 5914-5922.
"A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events." Pharm Stat 14, no. 4 (2015): 273-83.
"